Form 4: GE HealthCare Director Lloyd Howell Jr. Receives Significant Equity Award

GE HealthCare Technologies Inc. Director Lloyd Howell Jr. was granted 3,092 restricted stock units, increasing his beneficial ownership to 9,116 shares.

Summary

• On May 28, 2025, Lloyd Howell Jr., a Director of GE HealthCare Technologies Inc. (GEHC), acquired 3,092 shares of common stock.
• This acquisition was an award of restricted stock units (RSUs) with a transaction price of $0 per share.
• Following this transaction, Mr. Howell's direct beneficial ownership in GE HealthCare Technologies Inc. increased to 9,116 shares.
• The restricted stock units will vest 100% on the earlier of the company's next annual meeting of stockholders or May 28, 2026.
• Each restricted stock unit represents the right to receive one share of GE HealthCare common stock upon settlement.
• Settlement of vested restricted stock units may be deferred by the reporting person, in accordance with GE HealthCare's Non-Employee Director Compensation and Benefits Plan.

Sentiment

Score: 7

Explanation: The transaction is a routine equity award to a director, indicating ongoing commitment and alignment of interests, which is generally positive for corporate governance and investor confidence. It is an expected event that reinforces the director's stake in the company's future.

Positives

• The acquisition of 3,092 restricted stock units by Director Lloyd Howell Jr. demonstrates continued alignment of management interests with shareholder value.
• The increase in beneficial ownership to 9,116 shares by a director signals ongoing confidence in the company's future performance and long-term strategy.

Future Outlook

The vesting schedule for the restricted stock units indicates a future commitment of the director to the company's performance through at least May 28, 2026, or the next annual meeting, aligning their incentives with long-term value creation.

Industry Context

This transaction is a routine insider equity award, common across industries for compensating non-employee directors and aligning their interests with long-term shareholder value. It does not provide specific insights into broader healthcare industry trends or competitive dynamics.

Comparison to Industry Standards

• The grant of restricted stock units as part of director compensation is a standard practice in publicly traded companies, including those in the healthcare technology sector.
• This method aligns director incentives with shareholder interests by tying compensation to the company's stock performance over a vesting period.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction rather than a comparative analysis of compensation structures.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity award aligns the director's financial interests with those of shareholders, potentially fostering decisions that enhance long-term stock value and corporate governance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The restricted stock units are scheduled to vest on the earlier of GE HealthCare's next annual meeting of stockholders or May 28, 2026.
• Settlement of vested RSUs may occur according to the reporting person's deferral election under the company's Non-Employee Director Compensation and Benefits Plan.

Key Dates

Recommendation

Keywords

GE HealthCare Technologies Inc., GEHC, Form 4, Insider Transaction, Restricted Stock Units, Equity Award, Director Compensation, Beneficial Ownership